Osimertinib, also known by its brand name Osimert, is an oral tyrosine kinase inhibitor (TKI) that is primarily used to treat patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). Approved by the FDA in 2015, Osimertinib has proven to be an effective treatment option, prolonging progression-free survival and improving...

Dealing with a cancer diagnosis is never easy, but understanding your treatment options and learning how to manage them effectively can make a significant difference in your journey. Osimert 80 mg, also known as osimertinib, is a targeted therapy for patients with non-small cell lung cancer (NSCLC) who have a specific mutation in the epidermal growth factor receptor (EGFR) gene. As you embark...